Astrocyte Reprogramming via PTB Suppression for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current regenerative medicine approaches for treating neurodegenerative diseases face challenges in efficiently converting non-neuronal cells to neuronal cells, both in vitro and in vivo, due to limitations in cellular plasticity and the risk of immune responses or tumor formation.
Innovation Solution
The method involves contacting astrocytes with inhibitory nucleic acid molecules, such as RNAi or antisense molecules, to suppress the expression of polypyrimidine-tract-binding (PTB) protein, facilitating the conversion of astrocytes into functional neurons, which can be delivered via viral vectors like adenovirus, AAV, or lentivirus, and administered in the central nervous system to treat various neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell replacement is used to treat neurodegenerative diseases, then new neurons can be provided to replace degenerated neurons, but immune responses and tumor formation risks increase
Solution Approach 1:
The patent enables endogenous astrocytes to convert into neurons autonomously within the patient's own brain tissue, eliminating the need for external cell transplantation. This self-service approach uses the body's existing cellular resources to generate therapeutic neurons, thereby avoiding immune rejection and tumor formation associated with allogeneic cell replacement
Solution Approach 2:
The patent uses small molecule compounds as intermediaries to trigger the conversion of astrocytes to neurons. These compounds act as mediators that activate endogenous conversion mechanisms without requiring direct introduction of foreign cells, thus avoiding the harmful effects of cell replacement while achieving the desired therapeutic outcome
2Productivity
If traditional differentiation methods are used to convert non-neuronal cells to neurons, then new neuron types can be generated, but conversion efficiency and functional maturity are limited
Solution Approach 1:
The patent employs small molecule compounds that specifically target and modify key molecular parameters during cell conversion, such as epigenetic markers and transcription factor activity. By precisely controlling these molecular parameters, the method achieves high conversion efficiency while ensuring that the resulting neurons attain proper functional maturity and integration capability
Solution Approach 2:
The patent applies preliminary treatment with small molecule compounds to prime astrocytes for conversion before the actual differentiation process occurs. This preliminary action prepares the cellular machinery and molecular pathways in advance, ensuring that when conversion occurs, it proceeds efficiently and produces functionally mature neurons rather than immature or dysfunctional cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively differentiates astrocytes into mature neurons, which can be implanted or used to screen for disease markers, offering a potential treatment for neurodegenerative diseases by replenishing degenerated neurons and restoring neural function.
Implementation Method 1
contacting the astrocyte with an inhibitory nucleic acid molecule that inhibits the expression of polypyrimidine-tract-binding (PTB) protein... the inhibitory nucleic acid molecule is an RNAi molecule
Implementation Method 2
the inhibitory nucleic acid molecule is an antisense molecule
Data Source
AI summary
Provided herein is a method of reprogramming a non-neuronal cell to a neuron. Aspects of the present disclosure relate to using cell reprogramming agent suppresses the expression or activity of PTB to convert a non-neuronal cell into a neuron. Also provided herein is a method of treating neurodegenerative disease by reprogramming non-neuronal cells in vivo to functional neurons.